Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Telegram Restored on Apple App Store After Temporary Removal 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
SAN FRANCISCO, April 03, 2018 -- Hagens Berman Sobol Shapiro LLP alerts investors in Akorn, Inc. (NASDAQ:AKRX) to the May 7, 2018 Lead Plaintiff deadline in the securities class action pending in the United States District Court for the Northern District of Illinois. If you purchased or otherwise acquired Akorn securities between March 1, 2017 and February 26, 2018 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/AKRX
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing
On April 24, 2017 Defendants announced Akorn agreed to a merger with Fresenius SE & Co. KGaA (“Fresenius”).
Then, on February 26, 2018, Fresenius announced it is investigating Akorn’s alleged breaches of FDA data integrity requirements and that the merger’s consummation may be affected if the probe yielded evidence of wrongdoing.
This news drove the price of Akorn shares down $11.63, or over 38%, to close at $18.65 per share on February 27, 2018.
“Akorn investors have suffered enormous losses,” said Hagens Berman partner Reed Kathrein. “We’re focused on Defendants’ disclosures that may relate to the subject of the Fresenius investigation.”
Whistleblowers: Persons with non-public information regarding Akorn should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 70+ attorneys in 11 offices across the country. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 510-725-3000
